Biovitrum acquires promising anti-obesity drug leads from BioFocus

24-Sep-2004 - Chesterford Research Park, UK and Stockholm, Sweden. BioFocus plc., a world leader in drug discovery, and Biovitrum today announce that Biovitrum has acquired from BioFocus the rights to a promising research project in obesity. The research project, which currently is at the end of the lead ...

Global Genomics ab signs collaboration agreement with Rheoscience A/S

22-Sep-2004 - Global Genomics(SM) AB (Stockholm, Sweden) announced today that Rheoscience A/S (Roedovre, Denmark) has entered into an agreement for the use tangerine® gene expression profiling to study targets in metabolic diseases. Ulf Boberg, CEO at Global Genomics stated, "This agreement is yet another ...

Marathoning Mice Could Have Olympian Effects on Obesity

25-Aug-2004 - A molecular switch known to regulate fat metabolism appears to prevent obesity and turns laboratory mice into marathon runners, a Salk Institute study has found. The discovery of the switch could lead to treatments for obesity and disorders associated with it, such as heart disease and type 2 ...

Illumina to Perform Large-Scale Mouse Genotyping Study for the Wellcome Trust Centre

Study Designed to Measure Association between Genetic Variation and Metabolic and Behavioral Disorders

13-Aug-2004 - San Diego. Illumina, Inc. announced that they will generate over 25 million mouse genotypes for The Wellcome Trust Centre for Human Genetics at Oxford University under a fast-track services agreement signed between the two organizations. Wellcome Trust-funded researchers will use SNP (single ...

Medivir and Biovitrum Initiate Research Collaboration in Diabetes

19-Jul-2004 - Medivir and Biovitrum announce that they initiate a research collaboration to meet the significant and growing medical need in type 2 diabetes. The intent of the collaboration is to combine the strengths of the two companies and develop a candidate drug for type 2 diabetes. Biovitrum is ...

Xenon Genetics Inc. Changes Name to Xenon Pharmaceuticals Inc.

30-Jun-2004 - Vancouver. Xenon Genetics Inc. announced that, effective immediately, it has changed its name to Xenon Pharmaceuticals Inc. The new name more accurately reflects Xenon's drug discovery and development focus and the Company's goal of commercializing novel drugs. Xenon's new website address is: ...

Osi Pharmaceuticals' Subsidary Prosidion Acquires Dipeptidyl Peptidase IV Platform From Probiodrug AG

Includes Phase II Development Candidate P93/01

22-Jun-2004 - Melville, Oxford, Halle (Saale). OSI Pharmaceuticals, Inc., Prosidion Limited, a subsidiary of OSI focused on the discovery and development of diabetes and obesity therapeutics, and Probiodrug AG announced today that Prosidion has agreed to purchase a platform of Dipeptidyl Peptidase IV (DP-IV) ...

Rockefeller University to Study Genetic Roots of Obesity-Related Diseases Via Whole Genome Association Scans

High density GeneChip® research arrays to be used in comprehensive association study

09-Jun-2004 - Santa Clara: Affymetrix, Inc., announced that scientists at The Rockefeller University will use GeneChip® arrays to genotype more than 3,200 individuals at high density across the genome in one of the first large-scale genome-wide association studies ever undertaken. The Rockefeller research ...

CuraGen and TopoTarget A/S Announce License and Collaboration Agreement for Novel Phase I HDAC Inhibitor for Oncology

04-Jun-2004 - New Haven. and Copenhagen - CuraGen Corporation and TopoTarget A/S, announced a license and collaboration agreement to develop and commercialize PXD101, a novel histone deacetylase (HDAC) inhibitor for the treatment of solid and hematological cancers. PXD101 is currently in a Phase I clinical ...

Peptimmune is Granted Exclusive License from Genzyme to Develop and Commercialize Treatment for Metabolic Diseases

11-May-2004 - Genzyme Corporation and Peptimmune, Inc. today announced that Genzyme has granted an exclusive worldwide license to Peptimmune to develop and market a Genzyme investigational drug candidate for the treatment of obesity and other metabolic disease indications. Peptimmune plans to file an IND with ...